Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ICON is a diagnostics & research business based in the US. ICON shares (ICLR) are listed on the NASDAQ and all prices are listed in US Dollars. ICON employs 41,150 staff and has a trailing 12-month revenue of around $7.7 billion.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $231.05 |
|---|---|
| 52-week range | $171.43 - $279.80 |
| 50-day moving average | $209.03 |
| 200-day moving average | $213.04 |
| Wall St. target price | $257.33 |
| PE ratio | 40.4634 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $5.74 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $231.05 from 2023-01-26
| 1 week (2023-01-20) | -0.16% |
|---|---|
| 1 month (2022-12-27) | 19.57% |
| 3 months (2022-10-27) | 20.48% |
| 6 months (2022-07-27) | -0.32% |
| 1 year (2022-01-27) | -9.98% |
|---|---|
| 2 years (2021-01-27) | 11.14% |
| 3 years (2020-01-27) | 34.47% |
| 5 years (2018-01-26) | 99.92% |
Valuing ICON stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICON's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ICON's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, ICON shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ICON's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3268. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICON's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ICON's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion.
The EBITDA is a measure of a ICON's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $7.7 billion |
|---|---|
| Operating margin TTM | 10.95% |
| Gross profit TTM | $1.5 billion |
| Return on assets TTM | 3.02% |
| Return on equity TTM | 5.73% |
| Profit margin | 6.06% |
| Book value | $100.91 |
| Market capitalisation | $19 billion |
TTM: trailing 12 months
We're not expecting ICON to pay a dividend over the next 12 months.
ICON's shares were split on a 2:1 basis on 12 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ICON shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ICON shares which in turn could have impacted ICON's share price.
Over the last 12 months, ICON's shares have ranged in value from as little as $171.43 up to $279.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICON's is 1.0649. This would suggest that ICON's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
